SCHEMBL7863760

SCHEMBL7863760

Cc1[nH]c2ccccc2c1CCNC(=O)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.72
TDP1 Q9NUW8 2/20 0.72
PABPC1 P11940 1/20 0.68
ALOX15 P16050 1/20 0.68
ATM Q13315 1/20 0.68
HDAC3 O15379 2/20 0.60
HDAC1 Q13547 2/20 0.60
HDAC2 Q92769 2/20 0.60
HDAC4 P56524 1/20 0.60
HDAC7 Q8WUI4 1/20 0.60
HDAC10 Q969S8 1/20 0.60
HDAC11 Q96DB2 1/20 0.60
HDAC8 Q9BY41 1/20 0.60
HDAC6 Q9UBN7 1/20 0.60
HDAC9 Q9UKV0 1/20 0.60
HDAC5 Q9UQL6 1/20 0.60
MAPK1 P28482 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
ALDH1A1 P00352 3/20 0.57
KDM4E B2RXH2 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3384593 0.94 ATM (0.67) MAPTTDP1PABPC1ALOX15ATM
SCHEMBL3230209 0.92 ATM (0.69) MAPTTDP1PABPC1ALOX15ATM
SCHEMBL3235845 0.90 ATM (0.66) MAPTTDP1PABPC1ALOX15ATM
SCHEMBL3384743 0.90 MAPT (0.67) MAPTTDP1PABPC1ALOX15ATM
SCHEMBL3615253 0.90 ATM (0.69) MAPTTDP1PABPC1ALOX15ATM
SCHEMBL3385026 0.89 ATM (0.65) MAPTTDP1PABPC1ALOX15ATM
SCHEMBL3605297 0.89 ATM (0.65) MAPTTDP1PABPC1ALOX15ATM
SCHEMBL20242466 0.89 PABPC1 (0.75) MAPTTDP1PABPC1ALOX15ATM
SCHEMBL3384789 0.88 ATM (0.64) MAPTTDP1PABPC1ALOX15ATM
SCHEMBL3384994 0.88 MAPT (0.68) MAPTTDP1PABPC1ALOX15ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11077120-B2 Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto EMORY UNIVERSITY (US) 2021-08-03 US disclosed
US-20200085837-A1 Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto UNIV EMORY (US) 2020-03-19 US disclosed
US-10568889-B2 Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto EMORY UNIVERSITY (US) 2020-02-25 US disclosed
US-20170042905-A1 Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-02-16 US disclosed
WO-2001055107-A2 AROMATIC AMINES AND AMIDES ACTING ON THE MELANOCORTIN RECEPTORS MELACURE THERAPEUTICS AB (SE) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11077120-B2 Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto PTGER2, PTGES2, PTGES MAPT 3658/4885TDP1 3071/4885PABPC1 3522/4885
US-10568889-B2 Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto PTGER2, PTGES2, PTGER1 MAPT 4235/4885TDP1 3193/4885PABPC1 3437/4885
US-20200085837-A1 Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto PTGER2, PTGES2, PTGER1 MAPT 4235/4885TDP1 3193/4885PABPC1 3437/4885
US-20170042905-A1 Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto PTGER2, PTGES2, PTGER1 MAPT 4235/4885TDP1 3193/4885PABPC1 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.